Omorova Aizhan Nurlanovna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Omorova Aizhan Nurlanovna has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ihsan Khudhair Jasim
Department of Pharmaceutics, Faculty of Pharmacy, Al-Turath University, Baghdad, Iraq
2 shared publications - Mohd Faizan Siddiqui
International Medical Faculty, Osh State University, Osh City, Kyrgyzstan
2 shared publications - Romanbek Kalmatov
Osh State University
2 shared publications - Abdurakhmanov Baktyiar Omurbekovich
Osh State University
1 shared publication - Abzal Zhumagaliuly
Department of Public Health, Asfendiyarov Kazakh National Medical University, Kazakhstan
1 shared publication - Azhar Shadab1 shared publication
Latest Publications
- 15 April 2026
- Published by Publishing Center Science and Practice in Bulletin of Science and Practice
- Vol. 12 (4) , 194-203
Hormonal and Sexual Dysfunctions in Men Residing in Environmentally Unfavorable Conditions: A Clinical–Functional Analysis Using the ICF Framework
Male reproductive health is increasingly recognized as a sensitive indicator of environmental and population health. The aim of this study was to comprehensively assess hormonal status and sexual function in men of reproductive age living in regions with various types of adverse environmental exposure, with functional interpretation of the findings within the framework of the International Classification of Functioning, Disability and Health (ICF). A comparative cross-sectional study was conducted involving 216 men aged 25–45 years who were permanent residents of either environmentally favorable regions or areas predominantly affected by pesticide use, heavy metal contamination, or radionuclide exposure. Hormonal assessment included measurements of total testosterone, sex hormone–binding globulin (SHBG), and luteinizing hormone (LH). Sexual function was evaluated using the International Index of Erectile Function (IIEF), with a focus on erectile and orgasmic domains. Within the ICF framework, environmental exposure is considered an adverse environmental factor leading to impairments in endocrine body functions and subsequent limitations in activity and participation, clinically manifested as sexual dysfunction. The findings support the interpretation of sexual dysfunction as an early functional marker of environmentally mediated endocrine disruption and highlight the value of integrating hormonal and functional outcomes in environmental and reproductive health research. Men residing in environmentally unfavorable regions exhibited significantly lower total testosterone levels and elevated SHBG concentrations compared with controls, while LH levels did not differ significantly between groups. These hormonal alterations were accompanied by marked reductions in erectile and orgasmic function scores. The observed combination of decreased androgen bioavailability in the absence of compensatory LH elevation indicates functional hypogonadism rather than primary testicular failure.
- 15 April 2026
- Published by Publishing Center Science and Practice in Bulletin of Science and Practice
- Vol. 12 (4) , 194-203
Hormonal and Sexual Dysfunctions in Men Residing in Environmentally Unfavorable Conditions: A Clinical–Functional Analysis Using the ICF Framework
Male reproductive health is increasingly recognized as a sensitive indicator of environmental and population health. The aim of this study was to comprehensively assess hormonal status and sexual function in men of reproductive age living in regions with various types of adverse environmental exposure, with functional interpretation of the findings within the framework of the International Classification of Functioning, Disability and Health (ICF). A comparative cross-sectional study was conducted involving 216 men aged 25–45 years who were permanent residents of either environmentally favorable regions or areas predominantly affected by pesticide use, heavy metal contamination, or radionuclide exposure. Hormonal assessment included measurements of total testosterone, sex hormone–binding globulin (SHBG), and luteinizing hormone (LH). Sexual function was evaluated using the International Index of Erectile Function (IIEF), with a focus on erectile and orgasmic domains. Within the ICF framework, environmental exposure is considered an adverse environmental factor leading to impairments in endocrine body functions and subsequent limitations in activity and participation, clinically manifested as sexual dysfunction. The findings support the interpretation of sexual dysfunction as an early functional marker of environmentally mediated endocrine disruption and highlight the value of integrating hormonal and functional outcomes in environmental and reproductive health research. Men residing in environmentally unfavorable regions exhibited significantly lower total testosterone levels and elevated SHBG concentrations compared with controls, while LH levels did not differ significantly between groups. These hormonal alterations were accompanied by marked reductions in erectile and orgasmic function scores. The observed combination of decreased androgen bioavailability in the absence of compensatory LH elevation indicates functional hypogonadism rather than primary testicular failure.
- Open Access
- 14 November 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 120-129
Immune Response to Probiotics and Physical Activity: A Clinical Study
This study assessed the effect of probiotic supplementation on immune response in physically active males before and after exhausting exercise. With growing evidence linking gut health to immune function, the aim was to determine whether 12 weeks of probiotics could influence key immune markers in athletes. In this semi-experimental study, 28 male athletes (18–35 years) from sports centers in Osh City, Kyrgyzstan, who engaged in regular training (≥ 3 days/week for ≥ 3 years) were randomly assigned to probiotic or placebo groups. Baseline characteristics included age (20.98 ± 5.9 years), weight (62.3 ± 9.8 kg), height (168.2 ± 7.6 cm), BMI (22.05 ± 2.4 kg/m²), and VO₂ max (59.98 ± 8.8 ml/kg/min), with no significant differences between groups. Immune markers—cell blood count (CBC), C-reactive protein (CRP), and immunoglobulin A (IgA)—were monitored at rest and after exercise. Probiotic supplementation resulted in a significant increase in monocyte levels at rest and during activity compared to placebo. Within the probiotic group, lymphocyte, monocyte, and granulocyte percentages rose significantly during activity (p < 0.001). These results indicate that probiotics may positively modulate immune function in athletes under high physical stress. Given that intense training can suppress immunity and increase susceptibility to illness, probiotic use may enhance gut microbiota, supporting immune resilience. A balanced microbiome not only aids digestion and nutrient absorption but also plays a vital role in regulating inflammation and immune responses. These findings support probiotics as a potential strategy to maintain immune health in physically active populations, warranting further investigation into strain-specific effects and long-term benefits.
- 14 November 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 120-129
Open AccessImmune Response to Probiotics and Physical Activity: A Clinical Study
This study assessed the effect of probiotic supplementation on immune response in physically active males before and after exhausting exercise. With growing evidence linking gut health to immune function, the aim was to determine whether 12 weeks of probiotics could influence key immune markers in athletes. In this semi-experimental study, 28 male athletes (18–35 years) from sports centers in Osh City, Kyrgyzstan, who engaged in regular training (≥ 3 days/week for ≥ 3 years) were randomly assigned to probiotic or placebo groups. Baseline characteristics included age (20.98 ± 5.9 years), weight (62.3 ± 9.8 kg), height (168.2 ± 7.6 cm), BMI (22.05 ± 2.4 kg/m²), and VO₂ max (59.98 ± 8.8 ml/kg/min), with no significant differences between groups. Immune markers—cell blood count (CBC), C-reactive protein (CRP), and immunoglobulin A (IgA)—were monitored at rest and after exercise. Probiotic supplementation resulted in a significant increase in monocyte levels at rest and during activity compared to placebo. Within the probiotic group, lymphocyte, monocyte, and granulocyte percentages rose significantly during activity (p < 0.001). These results indicate that probiotics may positively modulate immune function in athletes under high physical stress. Given that intense training can suppress immunity and increase susceptibility to illness, probiotic use may enhance gut microbiota, supporting immune resilience. A balanced microbiome not only aids digestion and nutrient absorption but also plays a vital role in regulating inflammation and immune responses. These findings support probiotics as a potential strategy to maintain immune health in physically active populations, warranting further investigation into strain-specific effects and long-term benefits.
- Open Access
- 22 August 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 164-182
Targeting Microbiota and Liver Diseases: from Basic Prospective to Recent Advance Treatments
The diverse community of microorganisms residing in the human digestive tract, known as the intestinal microbiome, plays a crucial role in the development and progression of various liver diseases. Disruptions in the gut-liver axis have been associated with various liver conditions, including non-alcoholic fatty liver disease, alcoholic liver disease, viral hepatitis, cirrhosis of liver, and hepatocellular carcinoma. Intestinal dysbiosis can worsen liver disease by promoting systemic inflammation, influencing immune responses, and altering metabolic pathways. This review explores the intricate connection between gut microbiome and liver diseases, highlighting fecal microbiome transplantation as a potential therapeutic approach. Considering search through databases using keywords including “liver disease” AND “microbiome” we found 62 clinical trials out of total 3,303 articles on microbiome changes to find promising treatment of liver disease. Totally 55 articles were assessed, of which most of the studies were about using probiotics, the diet and exercise, and finally FMT. NAFLD was the most predominant liver disease targeted for intervention and treatment. Most of studies (47/55: 85.45%) reported targeting microbiome as an effective and promising treatment. Probiotics and prebiotics also show promise in mitigating liver dysfunction by modulating gut microbiome and influencing adipokines, key regulators in metabolic and inflammatory processes. Despite advancements, significant gaps persist, particularly regarding FMT applications in chronic viral hepatitis and HCC. Further clinical trials are essential to optimize gut microbiome-targeted therapies for liver disease management. This review emphasizes the need for a multidisciplinary approach to bridge the gap between microbial science and therapeutic innovations in hepatology.
- 22 August 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 164-182
Open AccessTargeting Microbiota and Liver Diseases: from Basic Prospective to Recent Advance Treatments
The diverse community of microorganisms residing in the human digestive tract, known as the intestinal microbiome, plays a crucial role in the development and progression of various liver diseases. Disruptions in the gut-liver axis have been associated with various liver conditions, including non-alcoholic fatty liver disease, alcoholic liver disease, viral hepatitis, cirrhosis of liver, and hepatocellular carcinoma. Intestinal dysbiosis can worsen liver disease by promoting systemic inflammation, influencing immune responses, and altering metabolic pathways. This review explores the intricate connection between gut microbiome and liver diseases, highlighting fecal microbiome transplantation as a potential therapeutic approach. Considering search through databases using keywords including “liver disease” AND “microbiome” we found 62 clinical trials out of total 3,303 articles on microbiome changes to find promising treatment of liver disease. Totally 55 articles were assessed, of which most of the studies were about using probiotics, the diet and exercise, and finally FMT. NAFLD was the most predominant liver disease targeted for intervention and treatment. Most of studies (47/55: 85.45%) reported targeting microbiome as an effective and promising treatment. Probiotics and prebiotics also show promise in mitigating liver dysfunction by modulating gut microbiome and influencing adipokines, key regulators in metabolic and inflammatory processes. Despite advancements, significant gaps persist, particularly regarding FMT applications in chronic viral hepatitis and HCC. Further clinical trials are essential to optimize gut microbiome-targeted therapies for liver disease management. This review emphasizes the need for a multidisciplinary approach to bridge the gap between microbial science and therapeutic innovations in hepatology.
- Open Access
- 28 March 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- Vol. 9 (2) , 45-59
Evaluating the Efficacy of Immunomodulatory Therapies in Rheumatoid Arthritis: A Clinical Study
Rheumatoid arthritis (RA) is a systemic autoimmune disorder driven by aberrant cytokine-mediated signalling that perpetuates synovial inflammation and joint destruction. Baricitinib, an oral Janus kinase-1/2 inhibitor, offers a mechanism-based therapeutic option; however, comparative data clarifying its broader immunomodulatory advantages remain limited. We conducted a 24-week, multicentre, double-blind, randomised controlled trial to compare the efficacy and safety of baricitinib with the tumour-necrosis-factor inhibitor adalimumab and with placebo in adults with moderate-to-severe RA who had an inadequate response to conventional synthetic DMARDs. Three hundred participants were allocated equally (1:1:1) to once-daily baricitinib 4 mg, subcutaneous adalimumab 40 mg every other week, or matched placebo, all on stable methotrexate. Co-primary endpoints were (i) mean change from baseline in the Disease Activity Score using 28 joints and C-reactive protein (DAS28-CRP) and (ii) the proportion of patients achieving clinical remission (DAS28-CRP < 2.6) at week 24. Secondary outcomes included the Health Assessment Questionnaire-Disability Index (HAQ-DI), 36-Item Short-Form Survey (SF-36), radiographic progression via modified Total Sharp Score (mTSS), and comprehensive safety assessments. Baricitinib achieved a greater DAS28 reduction (−3.3 ± 0.9) than adalimumab (−2.9 ± 0.8) and placebo (−1.5 ± 0.7), with remission rates of 50%, 45%, and 20%, respectively. Baricitinib also produced superior improvements in HAQ-DI and SF-36 and curtailed radiographic progression versus placebo. Adverse events—predominantly mild upper-respiratory infections—were more frequent with baricitinib, yet serious events were comparable across groups.
- 28 March 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- Vol. 9 (2) , 45-59
Open AccessEvaluating the Efficacy of Immunomodulatory Therapies in Rheumatoid Arthritis: A Clinical Study
Rheumatoid arthritis (RA) is a systemic autoimmune disorder driven by aberrant cytokine-mediated signalling that perpetuates synovial inflammation and joint destruction. Baricitinib, an oral Janus kinase-1/2 inhibitor, offers a mechanism-based therapeutic option; however, comparative data clarifying its broader immunomodulatory advantages remain limited. We conducted a 24-week, multicentre, double-blind, randomised controlled trial to compare the efficacy and safety of baricitinib with the tumour-necrosis-factor inhibitor adalimumab and with placebo in adults with moderate-to-severe RA who had an inadequate response to conventional synthetic DMARDs. Three hundred participants were allocated equally (1:1:1) to once-daily baricitinib 4 mg, subcutaneous adalimumab 40 mg every other week, or matched placebo, all on stable methotrexate. Co-primary endpoints were (i) mean change from baseline in the Disease Activity Score using 28 joints and C-reactive protein (DAS28-CRP) and (ii) the proportion of patients achieving clinical remission (DAS28-CRP < 2.6) at week 24. Secondary outcomes included the Health Assessment Questionnaire-Disability Index (HAQ-DI), 36-Item Short-Form Survey (SF-36), radiographic progression via modified Total Sharp Score (mTSS), and comprehensive safety assessments. Baricitinib achieved a greater DAS28 reduction (−3.3 ± 0.9) than adalimumab (−2.9 ± 0.8) and placebo (−1.5 ± 0.7), with remission rates of 50%, 45%, and 20%, respectively. Baricitinib also produced superior improvements in HAQ-DI and SF-36 and curtailed radiographic progression versus placebo. Adverse events—predominantly mild upper-respiratory infections—were more frequent with baricitinib, yet serious events were comparable across groups.
- Open Access
- 24 December 2024
- Published by Osh State University in Вестник Ошского государственного университета. Медицина
- No. 2(4),p. 40-46
BRONCHIAL ASTHMA IN CHILDREN: A CALL FOR ACTION IN DEVELOPING COUNTRIES
In underdeveloped nations where low resources and poor healthcare infrastructure impede accurate diagnosis and therapy, bronchial asthma in children is a significant public health issue. Children's health and quality of life are seriously threatened by this disorder, which is marked by coughing, dyspnea, and repeated wheezing, particularly when combined with environmental elements such pollution and poor air quality. Targeted treatments are desperately needed, as early childhood onset and a high frequency in socioeconomically poor areas highlight. Emphasizing the requirement of easily available diagnostic equipment, better treatment choices, and community education, this analysis exposes the crucial deficiencies in asthma therapy in poor countries. Reducing the burden of childhood asthma and enhancing the outcomes for impacted children depend on more investment in healthcare and greater emphasis on asthma-specific public health projects.
- 24 December 2024
- Published by Osh State University in Вестник Ошского государственного университета. Медицина
- No. 2(4),p. 40-46
Open AccessBRONCHIAL ASTHMA IN CHILDREN: A CALL FOR ACTION IN DEVELOPING COUNTRIES
In underdeveloped nations where low resources and poor healthcare infrastructure impede accurate diagnosis and therapy, bronchial asthma in children is a significant public health issue. Children's health and quality of life are seriously threatened by this disorder, which is marked by coughing, dyspnea, and repeated wheezing, particularly when combined with environmental elements such pollution and poor air quality. Targeted treatments are desperately needed, as early childhood onset and a high frequency in socioeconomically poor areas highlight. Emphasizing the requirement of easily available diagnostic equipment, better treatment choices, and community education, this analysis exposes the crucial deficiencies in asthma therapy in poor countries. Reducing the burden of childhood asthma and enhancing the outcomes for impacted children depend on more investment in healthcare and greater emphasis on asthma-specific public health projects.